OneSource Specialty Pharma (BOM:544292) EPS (Basic): ₹-4.24 (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:544292 OneSource Specialty Pharma Ltd BOM:544292
8 GF Score
Price ₹1,481.35
! 3 Warning Signs
View Full Analysis

What is OneSource Specialty Pharma EPS (Basic)?

OneSource Specialty Pharma BOM:544292 -2.04% 8 EPS (Basic) is ₹-4.24 as of Jun. 2026. GuruFocus rates BOM:544292 with a GF Score™ of 8/100. The stock has 3 warning signs investors should review.

OneSource Specialty Pharma's basic earnings per share (Basic EPS) for the three months ended in Jun. 2026 was ₹2.18. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-4.24.

OneSource Specialty Pharma's EPS (Diluted) for the three months ended in Jun. 2026 was ₹2.18. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 was ₹-4.25.

OneSource Specialty Pharma's EPS without NRI for the three months ended in Jun. 2026 was ₹2.41. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2026 was -3.44.

During the past 12 months, OneSource Specialty Pharma's average EPS without NRIGrowth Rate was -160.70% per year. During the past 3 years, the average EPS without NRI Growth Rate was 37.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 4 years, OneSource Specialty Pharma's highest 3-Year average EPS without NRI Growth Rate was 37.60% per year. The lowest was 37.60% per year. And the median was 37.60% per year.

OneSource Specialty Pharma  (BOM:544292) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

OneSource Specialty Pharma EPS (Basic) Related Terms

OneSource Specialty Pharma EPS (Basic) Historical Data

* Premium members only.

The historical data trend for OneSource Specialty Pharma's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OneSource Specialty Pharma EPS (Basic) Chart

OneSource Specialty Pharma Annual Data
Trend Mar23 Mar24 Mar25 Mar26
EPS (Basic)
-69.89 -34.18 -1.63 -6.44

OneSource Specialty Pharma Quarterly Data
Mar23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only -0.02 0.92 -7.74 0.40 2.18
BOM:544292
8GF Score
OneSource Specialty Pharma Ltd BOM:544292
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

OneSource Specialty Pharma EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

OneSource Specialty Pharma's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-738.03-0)/114.601
=-6.44

OneSource Specialty Pharma's Basic EPS for the quarter that ended in Jun. 2026 is calculated as

Basic EPS (Q: Jun. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(249.97-0)/114.665
=2.18

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-4.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹-4.24 mean?
OneSource Specialty Pharma (BOM:544292) has a EPS (Basic) of ₹-4.24 as of Jun. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on OneSource Specialty Pharma and its competitors.
Is OneSource Specialty Pharma's EPS (Basic) too high?
OneSource Specialty Pharma's current EPS (Basic) is ₹-4.24. Overall, OneSource Specialty Pharma has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does OneSource Specialty Pharma's EPS (Basic) compare to VRTX and REGN?
OneSource Specialty Pharma's EPS (Basic) of ₹-4.24 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Biotechnology company?
A good EPS (Basic) depends on the Biotechnology industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on OneSource Specialty Pharma and its competitors. OneSource Specialty Pharma's current EPS (Basic) is ₹-4.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OneSource Specialty Pharma stock overvalued right now?
OneSource Specialty Pharma (BOM:544292) has a current EPS (Basic) of ₹-4.24. The current EPS (Basic) is ₹-4.24. OneSource Specialty Pharma's overall GF Score™ is 8/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For OneSource Specialty Pharma (BOM:544292), the current EPS (Basic) is ₹-4.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OneSource Specialty Pharma Business Description

Other Exchanges ONESOURCE:India
Address Bannerghatta Road, Star 1, Opp IIM Bangalore, Bilekahalli, Bangalore, KA, IND, 560076
OneSource Specialty Pharma Ltd is engaged in the research, development, manufacture and commercialization of biological drug products in different injectable formats. The company also offers end-to-end CDMO services across all phases of pre-clinical and clinical development and commercial supply of biologics. The company's reportable segments are CDMO (Contract Development and Manufacturing Organization (CDMO) : Development and manufacture of pharmaceutical products and associated services); and Unit-3 Multimodal Facility and CDMO-2.
8GF Score

Get the complete analysis for BOM:544292

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,481.35
Price